biostudies-literatureSahakyan YCanada Research Chair in the Economics of Infectious Diseases held by Beate SanderCIHRCanadian Institute of Health Research (CIHR)1224https://www.ebi.ac.uk/biostudies/studies/S-EPMC11359558biostudies-literatureUnknown16(8)<h4>Background</h4>The World Health Organization (WHO) has set hepatitis C (HCV) elimination targets for 2030. Understanding existing gaps in the "HCV care-cascade" is essential for meeting these targets. We aimed to identify the level of service scale-up needed along the "HCV care-cascade" to achieve the WHO's HCV elimination targets in Ontario, Canada.<h4>Methods</h4>By employing a decision analytic model, we projected the quality-adjusted life years (QALYs) and healthcare costs for individuals with HCV in Ontario. We increased RNA testing and treatment rates to 98%, followed by increasing antibody testing uptake until we achieved the WHO's mortality target (i.e., a 65% reduction in liver-related mortality by 2030 vs. 2015).<h4>Results</h4>Without scaling up by 2030, the expected QALYs aVirusesBridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO's Targets in Ontario, Canada.PMC11359558FRN:201910MFE-430962-169632CRC-950-232429PJT-156066Sander BGreenaway CWong WWLKwong JCJanjua NSahakyan YErman AfalseBridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO's Targets in Ontario, Canada.<h4>Background</h4>The World Health Organization (WHO) has set hepatitis C (HCV) elimination targets for 2030. Understanding existing gaps in the "HCV care-cascade" is essential for meeting these targets. We aimed to identify the level of service scale-up needed along the "HCV care-cascade" to achieve the WHO's HCV elimination targets in Ontario, Canada.<h4>Methods</h4>By employing a decision analytic model, we projected the quality-adjusted life years (QALYs) and healthcare costs for individuals with HCV in Ontario. We increased RNA testing and treatment rates to 98%, followed by increasing antibody testing uptake until we achieved the WHO's mortality target (i.e., a 65% reduction in liver-related mortality by 2030 vs. 2015).<h4>Results</h4>Without scaling up by 2030, the expected QALYs a2024-01-01T00:00:00Z2024 Jul2026-04-22T03:13:15.722Z2025-04-05T12:31:25.044ZS-EPMC113595583920519810.3390/v16081224